Vikas Lifecare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Results View source PDF Explain this filing

VIKASLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹2.26

prior close

₹2.23

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-1.9% vs market

Trading & Distributors peers, median of 129sector-0.1%-1.7% vs sector

On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.7 pts less than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.0

15m

+0.4

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8+0.2-1.9-0.1-1.7

Next day

-1.3+0.6-1.9-0.0-1.3

-0.4+0.5-0.9-0.1-0.4

-1.3+0.4-1.8-0.5-0.8

-0.4+1.2-1.6-0.3-0.2

+0.4+1.7-1.3-0.4+0.9

+3.5+2.1+1.4+0.3+3.3

15d

-2.7-3.3+0.6-1.9-0.7

-4.4-1.3-3.2-1.8-2.6

-10.6-0.9-9.8-2.2-8.4

-19.0-5.6-13.5-9.2-9.9

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 129Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vikas Lifecare Limited has submitted its financial results for the quarter ended June 30, 2025 to the NSE exchange. This is a routine quarterly compliance filing under listing obligations, covering what would be Q1 FY2026 results. The actual numbers, including revenue, profit/loss, and margins, are contained in the attached results document rather than this brief filing notice. Investors should refer to the detailed financial result PDF for performance specifics.

Likely market impact

This is a standard regulatory filing with no immediate price impact on its own. Shareholders should review the attached detailed results to assess the company's quarterly performance and any year-on-year or sequential changes in key financial metrics.